Press Release (ePRNews.com) - Ann Arbor, Michigan - May 12, 2017 - GreenMark Biomedical Inc. today announced that it has been selected to present at the 36th annual Michigan Growth Capital Symposium (MGCS) and the jointly hosted Coulter Investment Forum. GreenMark, a Delaware corporation with facilities in Michigan, will be presenting to investors in attendance, including more than 100 top venture capital firms. The company aims to deliver health benefits to society through biobased targeting technologies.
GreenMark is developing and marketing next generation diagnostics and therapeutics for dental cavities (tooth decay), which is the most prevalent chronic disease worldwide. Its founder, Dr. Steven Bloembergen, has extensive experience and business success with starch nanoparticle technology as co-founder of EcoSynthetix Inc. (TSX: ECO), a company with global sales and production. GreenMark was spun out in 2016 to develop dental and medical applications. “Existing diagnostic tools available to the dentist are inadequate, especially in view of new developing paradigms in dentistry. Our diagnostic based on food-grade starch will assist dentists in early detection and improved management of tooth decay, leading to better oral health outcomes for patients. The particles are targeted inside early cavities and these are illuminated using a standard dental curing light found in all practices. Natural enzymes in our saliva are designed to degrade starch, making this an ideal carrier.”
“GreenMark is developing and marketing next generation diagnostics and therapeutics for dental cavities (tooth decay), which is the most prevalent chronic disease worldwide.”
Bloembergen explains and adds: “This makes for an exciting business opportunity that we hope will change the way dentistry is done, allowing dentists to do the right thing while increasing clinic income.” The company’s pipeline of products includes other exciting dental and medical applications. Bloembergen, GreenMark’s Chairman and CEO, will be presenting at the MGCS forum. The company is looking to raise $3.0 million in support of its commercialization plan.
First held in 1981, MGCS is the premier, must-attend event for venture capitalists, technology transfer professionals, founders, CEOs and the best of the Midwest early stage and emerging, high-growth companies that are seeking institutional investment. The two-day conference will feature keynote addresses from Clay Thorp, general partner of Hatteras Venture Partners, and Markus Lampinen, CEO of Crowd Valley, along with engaging panel discussions and unmatched networking opportunities for attendees.
More than 500 entrepreneurs, researchers, investment professionals and business executives are expected to attend the Symposium, which will be held May 16-17 at the Marriott Resort in Ypsilanti, Mich. The evening reception on the opening day of the conference at the University of Michigan’s football stadium will provide attendees the chance to network on and off the field.
“The Symposium plays a vital role in the Midwest’s entrepreneurial ecosystem, creating a platform for high-growth companies to make their case to investors and access new sources of funding,” said David Brophy, Michigan Growth Capital Symposium founder and director of the University of Michigan’s Center for Venture Capital & Private Equity. “I am continually impressed by the caliber of companies that join us to present year after year, and we are glad to have GreenMark Biomedical join the ranks for this year’s special event with the Coulter Investment Forum.”
To learn more, see the full list of presenting companies or register for the conference, visit www.michigan-gcs.com, and follow conversations about the Symposium by tracking #MichiganGCS on Twitter. For more information about GreenMark Biomedical, please visit http://greenmark.bio.
About GreenMark Biomedical Inc.
GreenMark’s central concept is the bio-delivery of health solutions on target, precisely where they are needed. The company has patented, patent-pending and proprietary technologies that use different grades of biobased nanoparticles uniquely modified into novel products that have built-in targeting performance for diagnostic and therapeutic dental and medical applications.
About the Michigan Growth Capital Symposium
The Michigan Growth Capital Symposium (MGCS) is the original university-based venture investment fair, which was first held in 1981. This decades-old nationally attended event is the largest Midwest fair of its kind that brings together venture capital investors, business angels, start-up companies, university tech transfer officers and research faculty. MGCS provides an opportunity for participants from the venture capital community to connect with Midwest start-ups seeking funding and to learn about emerging innovations that span tech and the life sciences. MGCS is presented by the Center for Venture Capital & Private Equity Finance and the Zell Lurie Institute at the University of Michigan Ross School of Business, with support from the Michigan Venture Capital Association.
Press Contact: Dr. Steven Bloembergen, GreenMark Biomedical Inc., 325 E. Grand River Avenue, Suite 314, East Lansing, MI 48823-4375. Contact: email@example.com or (517) 896-3665. Source :
GreenMark Biomedical Inc.